Episode 64 - What the Research Says About Ketamine for Postpartum Depression
Perinatal Depression and Ketamine Therapy: An Evidence-Based Review for Providers
An evidence-based review of what the latest ketamine and esketamine trials actually show about postpartum depression prevention and treatment, and what it means for your practice.
Postpartum depression affects roughly 10 to 20 percent of mothers and remains one of the most undertreated conditions in medicine. As public awareness of maternal mental health grows, providers in the ketamine and psychedelic therapy space are increasingly asking: is there a role for ketamine or esketamine here?
This episode is our evidence-based answer to that question.
We walk through the current clinical literature on ketamine and esketamine for perinatal depression, drawing on randomized controlled trials, meta-analyses, and expert commentary from institutions including the Center for Women's Mental Health at Massachusetts General Hospital. The research landscape is more nuanced than most providers realize, and understanding it clearly matters both for patient conversations and for how you think about your practice's scope.
One distinction shapes everything that follows in this episode, and it's an important one: virtually all of the existing trial data involves perioperative prevention in cesarean delivery populations, not outpatient treatment of established postpartum depression. Knowing what the evidence actually supports and where the gaps remain is essential context for any provider working in this space.
What You'll Learn in This Episode:
A clear breakdown of what current ketamine and esketamine trials actually show for postpartum depression prevention, and what limited data exist for treatment.
An understanding of why racemic ketamine and esketamine tell different stories in the peripartum literature.
The key ethical and practical considerations for any provider thinking about this population.
An honest framework for how to talk with patients who ask about ketamine for postpartum depression.
Context on what the research gaps mean for where this field is heading.
Key Takeaways
The peripartum evidence for esketamine is more consistent and durable than for racemic ketamine, particularly in women with existing antenatal depressive symptoms.
Almost all of the existing trial data involves prevention around cesarean delivery, not treatment of established postpartum depression in an outpatient setting.
The mixed peripartum data for racemic ketamine do not reflect on its well‑established role in treating TRD, which is a separate and more robust evidence base.
Postpartum psychosis is a psychiatric emergency that generally warrants avoiding ketamine or using it only with extreme caution, and it should not be conflated with postpartum depression.
The research population in most of these trials is specific: women undergoing cesarean delivery in tertiary hospital settings, primarily in China, which can limit direct translation to U.S. outpatient practice.
Cautious optimism is warranted; broad clinical adoption is not.
Review the research behind this episode, including full citations for every study discussed, in the Clinical References and Further Reading section below.
Listen to the episode on Apple Podcasts, Spotify, Overcast, or on your favorite podcast platform. Watch the discussion on YouTube here.
Episode 64 show notes:
00:00:06 Episode Introduction
00:02:02 Clinical Context: Defining PPD, Postpartum Psychosis, and Perinatal Depression
00:03:34 Prevalence, Public Health Burden, and Why Cesarean Delivery Matters Here
00:04:40 Why Ketamine and Esketamine Are Conceptually Interesting in This Population
00:05:38 Prevention vs. Treatment: A Critical Framing Point Before the Research
00:06:32 Racemic Ketamine in the Peripartum Setting: Mixed and Conflicting Signals
00:09:22 What the Meta-Analyses Tell Us: Darwish et al. 2025 and Li et al. 2024
00:11:18 Bottom Line on Racemic Ketamine in the Peripartum Setting
00:12:05 Esketamine: Why It May Outperform Racemic and Why This Is Not About Spravato
00:13:32 The Esketamine Trials: From Early Signals to the 2024 BMJ Landmark Study
00:18:51 Treatment vs. Prevention: What About Established PPD?
00:21:29 Ethical and Practical Considerations
00:21:40 Lactation and Infant Exposure
00:22:14 Neurodevelopment Data: The Long-Term Unknown
00:22:35 Informed Consent in the Peripartum Period
00:23:04 The Tension Between Rapid Relief and Premature Clinical Adoption
00:24:10 Clinical Takeaways, Research Gaps, and What Cautious Optimism Looks Like in Practice
00:24:27 What the Evidence Supports: Esketamine Summary
00:25:23 What the Evidence Does Not Yet Support: Outpatient PPD Use
00:25:41 Bottom Line on Racemic Ketamine: Summary
00:26:07 Five Research Gaps the Field Needs to Address
00:27:56 What This Data Means for Ketamine Therapy Providers Right Now
00:30:03 Closing Remarks
Thanks for listening
Prefer to read? This episode has a companion blog post covering the same evidence with structured comparison tables breaking down racemic ketamine versus esketamine and the five key research gaps the field still needs to address.
Read the Blog Post →Clinical Research Disclaimer: This episode is intended for licensed healthcare professionals and is for educational purposes only. The studies discussed involve specific peripartum populations—primarily women undergoing cesarean delivery in tertiary hospital settings—and their findings should not be generalized to routine practice without careful consideration of your own patient population, clinical setting, and prevailing standards of care.
The use of ketamine or esketamine for prevention or treatment of postpartum depression is not FDA‑approved and should be regarded as off‑label and investigational in this specific population. Nothing in this episode constitutes medical advice for individual patients or endorsement of any particular protocol, nor does it recommend expanding your scope of practice into perinatal care without appropriate training and collaborative care.
Clinical research in this area is evolving rapidly. The information presented reflects the published literature available at the time of recording and may not capture subsequent developments. Treatment decisions should always be based on individual patient assessment, up‑to‑date evidence, and adherence to your professional medical and ethical standards. Always consult qualified medical, legal, and regulatory professionals before making significant clinical or practice decisions.
Research in this area is evolving. The information presented reflects the literature available at the time of recording and may change as new data emerge. Treatment decisions should always be based on up‑to‑date evidence, individual clinical judgment, and your professional medical and ethical standards.
Frequently Asked Questions
Is ketamine approved for treating postpartum depression?
No. Neither racemic ketamine nor esketamine is currently FDA‑approved specifically for postpartum depression. The overwhelming majority of clinical trial data in this area involves perioperative prevention in women undergoing cesarean delivery, not outpatient treatment of established PPD. Esketamine (Spravato) is FDA‑approved for treatment‑resistant depression and for major depressive disorder with acute suicidal ideation or behavior, but not specifically for postpartum depression. Any use of ketamine or esketamine in a postpartum population would be considered off‑label and should be approached with careful clinical judgment, thorough informed consent, and ideally in close coordination with the patient’s obstetric and psychiatric team.
What is the difference between what the racemic ketamine and esketamine data show for postpartum depression?
Peripartum data for racemic ketamine are mixed and inconsistent across trials. Some randomized studies show short‑term reductions in PPD risk—particularly in high‑risk women with antenatal depressive symptoms—but these effects tend to attenuate by four to six weeks postpartum and are not uniform across the literature. Updated meta‑analyses conclude that racemic ketamine reduces short‑term PPD incidence but does not maintain a significant preventive effect at longer follow‑up and therefore do not support routine prophylactic use.
Esketamine shows a more consistent and durable preventive effect. Multiple randomized controlled trials and meta‑analyses demonstrate meaningful reductions in PPD incidence and EPDS scores at one week and around six weeks postpartum, especially in women with antenatal depressive symptoms or other risk factors, and often with concurrent analgesic benefit. Importantly, this difference in the peripartum literature does not reflect negatively on racemic ketamine’s well‑established efficacy for treatment‑resistant depression in non‑peripartum populations, which rests on a separate and more robust evidence base.
Can I offer ketamine therapy to patients with postpartum depression in my outpatient clinic?
The current evidence base does not yet support a clear, evidence‑based protocol for outpatient ketamine treatment of established postpartum depression. Existing trial data are almost entirely focused on perioperative prevention in cesarean delivery or labor‑analgesia settings, not on clinic‑based treatment of diagnosed PPD. A 2022 narrative review identified only four clinical trials or reports examining ketamine in a treatment‑oriented postpartum context and concluded that, while the approach is promising, evidence is insufficient to support routine use.
If you have a postpartum patient you believe might benefit from ketamine therapy, that conversation should involve her obstetric provider and, ideally, a perinatal psychiatrist. It should include a careful, documented informed consent process addressing lactation and infant exposure and a shared understanding that this represents investigational use in this specific population, even though ketamine may be well supported for TRD outside the perinatal window.
Is postpartum psychosis a contraindication for ketamine therapy?
Postpartum psychosis is generally considered a contraindication or situation requiring extreme caution for ketamine therapy. It is a rare but serious psychiatric emergency characterized by hallucinations, delusions, and disorganized thinking, and is distinct from postpartum depression. Ketamine practice guidelines and perinatal mental health reviews advise avoiding ketamine in patients with active psychotic symptoms or psychotic disorders due to the risk of exacerbating psychosis. Providers should ensure they clearly differentiate postpartum depression from postpartum psychosis before making any clinical decisions about ketamine in a postpartum patient.
What are the key ethical considerations for providers thinking about ketamine in postpartum patients?
There are four primary considerations worth thinking through carefully:
Lactation and infant exposure: Ketamine and esketamine can be excreted into breast milk, and clinical guidance on nursing after administration is sparse and not well standardized. Most peripartum ketamine/esketamine trials did not systematically assess breastfeeding outcomes or infant effects. Any provider considering this population needs an explicit, documented conversation with the patient and her obstetric (and pediatric) team about breastfeeding timing and practices.
Neurodevelopmental data: Long‑term follow‑up data on children of mothers who received ketamine or esketamine peripartum are essentially absent from the current literature. Follow‑up in trials is typically limited to days or several weeks postpartum and focuses on maternal mood and pain, not child neurodevelopment. Patients deserve to know that we do not yet have answers to these longer‑term questions.
Informed consent complexity: Obtaining truly informed consent in the immediate peripartum period—during labor, recovery from surgery, or early postpartum—requires careful attention to the patient’s emotional and physiological state, potential pain, and cognitive load. This is less of an issue for outpatient treatment of established PPD, but it is a real consideration in anesthesia‑adjunct models.
Balancing urgency with evidence: Severe or suicidal postpartum depression is a psychiatric emergency, and the appeal of rapid relief from ketamine’s fast‑acting antidepressant effects is real. However, the treatment‑focused evidence base in postpartum populations is thin, and clinical infrastructure for safe peripartum ketamine use outside of hospital anesthesia contexts is not yet well defined. Compassion and caution need to coexist.
Does the esketamine data from these trials apply to Spravato?
Not directly. The esketamine trials discussed in this episode used intravenous esketamine formulations administered in hospital and research settings as part of perioperative anesthetic and analgesic protocols, and were funded by government and hospital sources rather than pharmaceutical companies. Spravato is an intranasal branded esketamine product approved for specific indications (treatment‑resistant depression and MDD with acute suicidal ideation or behavior) in outpatient clinical settings under a REMS program. The pharmacological compound is the same S‑enantiomer, but the formulation, route of administration, dosing protocols, clinical context, and patient population are different. The peripartum IV esketamine data should not be interpreted as direct evidence for Spravato’s use in postpartum populations.
Clinical References & Further Reading
Clinical Background and Burden of Perinatal Depression
BMJ Best Practice. Postpartum Depression. https://bestpractice.bmj.com/topics/en-us/512
StatPearls. Postpartum Depression. https://www.ncbi.nlm.nih.gov/books/NBK519070/
American Psychiatric Association. What is Peripartum Depression? https://www.psychiatry.org/patients-families/peripartum-depression/what-is-peripartum-depression
Racemic Ketamine: Peripartum Trials
Esketamine: Peripartum Trials
Meta-Analyses and Systematic Reviews
Treatment of Established PPD and Ethical Considerations
General Resources and Expert Commentary
Center for Women's Mental Health, Massachusetts General Hospital. Is Ketamine or Esketamine an Option for the Treatment of Postpartum Depression? https://womensmentalhealth.org/posts/ketamine-esketamine-for-postpartum-depression/